Marginal zone lymphoma
Prepared with OnCo (onco.cc/prep/marginal-zone-lymphoma/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
15 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example Helicobacter pylori status, tMALT1 translocation, Hepatitis C serology, MYD88 wild-type, Plasmacytic differentiation and paraprotein), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (gastric malt lymphoma, h. pylori-positive), which of the standard options do you recommend and why?
- 6.For my situation (localised extranodal disease), which of the standard options do you recommend and why?
- 7.For my situation (splenic marginal zone lymphoma), which of the standard options do you recommend and why?
- 8.Am I a candidate for Rituximab, and what side effects should I expect?
- 9.For my situation (advanced or relapsed), which of the standard options do you recommend and why?
- 10.Am I a candidate for Rituximab, Bendamustine, Chlorambucil or related drugs, and what side effects should I expect?
- 11.Are there clinical trials I could join, for example of Zanubrutinib, Lenalidomide?
- 12.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 13.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
- 14.I read that “Transformation to diffuse large B-cell lymphoma in a minority”. How does that affect my plan?
- 15.I read that “No standard sequence of therapies is proven by randomised trials”. How does that affect my plan?
Tests and results to bring
Biomarker results to ask for: Helicobacter pylori status (gastric MALT), t(11;18) MALT1 translocation (predicts failure of eradication therapy), Hepatitis C serology (splenic), MYD88 wild-type (distinguishes from Waldenstrom), Plasmacytic differentiation and paraprotein.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Localised extranodal disease: Low-dose involved-site radiotherapy (as little as 4 Gy in two fractions for some sites); surgery rarely. (IMRT / IGRT (modern external beam), Hypofractionated radiotherapy)
- Gastric MALT lymphoma, H. pylori-positive: Eradication therapy and endoscopic follow-up; radiotherapy if the lymphoma persists or carries t(11;18). (Non-Hodgkin lymphoma (all types))
- Splenic marginal zone lymphoma: Watch and wait if asymptomatic; antiviral therapy if hepatitis C-positive; rituximab alone or with chemotherapy; splenectomy now rare. (Rituximab)
- Advanced or relapsed: Rituximab with bendamustine or chlorambucil, lenalidomide-rituximab; zanubrutinib or ibrutinib for relapsed disease. (Rituximab, Bendamustine, Chlorambucil, Lenalidomide, Zanubrutinib, Ibrutinib)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.